The Experimental Research About The Expression Of Enzymes Involved In Sexual Hormone Metabolism In Human Breast Tissue

Breast cancer is one of the most frequent female malignant tumors, which occupies 7%~10% of the whole malignant tumor. The morbidity of breast cancer has been in increasing trend in the past few years. The survival rate of the patients with breast cancer greatly improved because of the compound treatment model based on surgery, radiotherapy, chemotherapy and endocrine therapy. The sexual hormone is related to the developmnt of breast carcinoma. Breast carcinoma has the intracrine behavior. It has the expression of the enzymes involved in the synthesis of estrogen and androgen in breast cancer tissues, The biologically potent estrogen which was synthesized itself plays a very important role in the proliferation of breast carcinoma cell and the blockade to the potential way would decrease the proliferation of breast carcinoma cells and improve the prognosis of the patients with breast carcinoma. Endocrine therapy promotes the remission by changing the hormone-dependent endocrine micro-environment which is necessary to tumor growth, which causes the proliferation of tumour cell stagnate in the G0/G1 stage, thus improves the quality of life of the patient. Compared to radiotherapy and chemotherapy, it seldom affect the normal cell and has little side effect and long remission. At present, the main medicine for endocrine therapy include estrogen receptor antagonist, whose major drug is tamoxifen, aromatase inhibitor. Because the aromatase inhibitor can't totally inhibit the activity of estradiol and the TAM develops resistance and carcinogenicity, seeking for more efficient and specific drug is the future direction of endocrine therapy.In this experiment, we study the expression of the enzyme involved in transformation between E1 and E2 in benign and malignant breast tumors tissues in RT-PCR method, which include 17βHSD12, 17βHSD7, 17βHSD1 and 17βHSD2.We find that the expression rate of 17βHSD12 in benign and malignant breast tissue was 67%and 97% respectively, and there is a significant difference, the expression rate of 17βHSD12 is 100% in postmenopausal patient bearing breast cancer, the expression rate of 17βHSD7 and 17βHSD1 have no significant difference between benign and malignant tumor tissues, which suggesting that 17βHSD12 plays an important role in the occurrence of breast carcinoma. 17βHSD12 have the potential to became the target of endocrine therapy.